Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?

Novo Nordisk (NYSE: NVO) got fantastic news last year when regulators approved its weight loss pill. It's the first oral GLP-1 drug in the market, and it unlocks a huge new growth opportunity for the business. While its injectable drugs have been doing well, a pill can be easier to produce at scale, and it's a more convenient option for people, particularly those who don't want to use needles. Shares of Novo Nordisk have been flying out of the gate in 2026 and they're up around 26% as of Jan. 26. By compa ...